7-5/2021/EU/WC-0500
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organisation
(International Cell)

FDA Bhawan, Kotla Road, New Delhi-110002 Dated

6 MAY 2021

To

M/s. Vadivarhe Speciality Chemicals Limited
GAT No. 204, Nashik-Mumbai Highway
At Post Wadhivarhe, Tal: Igatpuri, District: Nashik – 422 403
Maharashtra, India

SUB:- Written Confirmation of M/s. Vadivarhe Speciality Chemicals Limited, GAT No. 204, Nashik-Mumbai Highway, At Post Wadhivarhe, Tal: Igatpuri, District: Nashik – 422 403, Maharashtra, India as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India-Reg.

Sir.

0/6

Please refer to your application submitted to CDSCO, West Zone office, and the recommendation received from DDC (I), West Zone on the above noted subject.

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions:-

- The Active Pharmaceutical Ingredients shall confirm to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).
- The manufacturer is subject to regular, strict and transparent controls and to the
 effective enforcement of Good Manufacturing Practice, including repeated and
 unannounced inspections, so as to ensure a protection of public health equivalent
 to that in the EU.
- 3. The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.
- 4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.
- 5. The Written Confirmation will be withdrawn in the events of non compliance of Standards.

- 6. This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.
- 7. In the event of any Non Compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.
- 8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.

Please acknowledge the receipt.

Annexure No.	No. of Products	Date of Issue	Valid Upto
ilo orko∑tastW	00000 01 being	0 6 MAY 2021	Three year from date of issue

est the least ociment of Good Manufacturing Fractice, including tapeaced and

neth Wild eusel for the muode constitute and water of perioder to test the first

Light Confirmation shall be produced by the Annouved Expodes

Yours faithfully,

(Dr. V. G. Somani) Drugs Controller General (India)

COSCO va Salitat de Alla Tipo

dia)



CERTIFICATE NO.:

WC-0500

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site:

M/s. Vadivarhe Speciality Chemicals Limited

GAT No. 204, Nashik-Mumbai Highway

At Post Wadhivarhe, Tal: Igatpuri, District: Nashik - 422 403

Maharashtra, India

2. Manufacturer's licence number: Form 25: 25-NK/25/NKD/106

Regarding the manufacturing plant under (1) of the following Active substance(s) exported to the EU for medicinal products for human use

List of API(s):

SP No. 14 TANK OF BUREA DESIGNATION (DESIGNATION)	JENTRAL DRUGS STANDARD STANDARD STANDARD OF THE MALIE Y WELL
Sr. No. Active substance (s)	A FAMILY WAS A STATE OF THE BEST OF THE STATE OF THE STAT
1. Clotrimazole USP	Activity(ies)
TEALTH & FAMILY WELFARE BRIMETER THE PARKET OF THE PARKET	Manufacturing & Packing

The issuing Regulatory Authority hereby confirms that:

The standards of good manufacturing practice applicable to this manufacturing plant are at least equivalent to those laid down in the EU (= GMP of WHO/ICH Q7);

The manufacturing plant is subject to regular, strict and transparent controls and to the effective enforcement of good manufacturing practice, including repeated and unannounced inspections, so as to ensure a protection of public health at least equivalent to that in the EU; and

In the event of findings relating to non-compliance, information on such findings is supplied by

Date of Inspection of the plant:

04.12.2019 & 05.12.2019

The Written Confirmation remains valid until: Three years from date of issue

The authenticity of this written confirmation may be verified with the issuing regulatory authority.

This written confirmation is without prejudice to the responsibilities of the manufacturer to ensure the quality of the medicinal product in accordance with Directive 2001/83/EC.

Address of the issuing regulatory authority: Central Drugs Standard Control Organisation

FDA Bhawan, Kotla Road, New Delhi- 110 002, India

Name and function of responsible person:

Dr. V. G. Somani,

Drugs Controller General (India)

E-mail:

Telephone no.:

dci@nic.in.

Fax no .:

+91-11-2323696

Signature

+91-11-232369